Ruxolitinib versus best available therapy in patients with essential thrombocythemia: Pre-specified interim analysis of the randomized phase 2b ruxobeat clinical trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

According to data from the pre-specified interim analysis of the randomized phase 2b RuxoBEAT trial—presented during the 2022 American Society of Hematology Annual Meeting—ruxolitinib did not induce a superior complete response over best available therapy (CR: 0% vs. 1.9% [p=1.0] CR+PR: 58.1% vs. 76.9% [p=0.075]) in ET patients that were either untreated or not intolerant/resistant to prior therapy. Ruxolitinib was more effective in reducing ET-associated spleen size and symptoms, such as headache and concentration problems.